196 related articles for article (PubMed ID: 27326256)
1. Expression of Polo-Like Kinase 4(PLK4) in Breast Cancer and Its Response to Taxane-Based Neoadjuvant Chemotherapy.
Li Z; Dai K; Wang C; Song Y; Gu F; Liu F; Fu L
J Cancer; 2016; 7(9):1125-32. PubMed ID: 27326256
[TBL] [Abstract][Full Text] [Related]
2. Aberrant expression of polo-like kinase 4 in renal cell carcinoma: Association with clinicopathological characteristics and long-term survival.
Jiang W; Zhao Y; Zhang S; Zeng Y; Ma J
Oncol Lett; 2022 Dec; 24(6):427. PubMed ID: 36311683
[TBL] [Abstract][Full Text] [Related]
3. Polo-like kinase 4 is associated with advanced TNM stages and reduced survival and its inhibition improves chemosensitivity in colorectal cancer.
Duan Z; Cai L; Cao J; Wu W
Oncol Lett; 2022 Aug; 24(2):269. PubMed ID: 35782899
[TBL] [Abstract][Full Text] [Related]
4. Polo-like kinase 4 correlates with greater tumor size, lymph node metastasis and confers poor survival in non-small cell lung cancer.
Zhou Q; Fan G; Dong Y
J Clin Lab Anal; 2020 Apr; 34(4):e23152. PubMed ID: 31876063
[TBL] [Abstract][Full Text] [Related]
5. Polo-like kinase 4 as a potential predictive biomarker of chemoradioresistance in locally advanced rectal cancer.
Oh H; Kim SG; Bae SU; Byun SJ; Kim S; Lee JH; Hwang I; Kwon SY; Lee HW
J Pathol Transl Med; 2022 Jan; 56(1):40-47. PubMed ID: 34775733
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of polo-like kinase 4 in hepatocellular carcinoma associates with poor prognosis.
Liu L; Zhang CZ; Cai M; Fu J; Chen GG; Yun J
PLoS One; 2012; 7(7):e41293. PubMed ID: 22829937
[TBL] [Abstract][Full Text] [Related]
7. Predictive value of BRCA1/2 mRNA expression for response to neoadjuvant chemotherapy in BRCA-negative breast cancers.
Xu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Cancer Sci; 2018 Jan; 109(1):166-173. PubMed ID: 29047188
[TBL] [Abstract][Full Text] [Related]
8. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
9. [Correlation of metastasis-free survival in patients with breast cancer and changes in the direction of expression of multidrug resistance genes during neoadjuvant chemotherapy].
Litviakov NV; Garbukov EIu; Slonimskaia EM; Tsyganov MM; Denisov EV; Vtorushin SV; Khristenko KIu; Zav'ialova MV; Cherdyntseva NV
Vopr Onkol; 2013; 59(3):334-40. PubMed ID: 23909034
[TBL] [Abstract][Full Text] [Related]
10. Significance of Tumor-Infiltrating Lymphocytes and the Expression of Topoisomerase IIα in the Prediction of the Clinical Outcome of Patients with Triple-Negative Breast Cancer after Taxane-Anthracycline-Based Neoadjuvant Chemotherapy.
Rao N; Qiu J; Wu J; Zeng H; Su F; Qiu K; Wu J; Yao H
Chemotherapy; 2017; 62(4):246-255. PubMed ID: 28472798
[TBL] [Abstract][Full Text] [Related]
11. Predictive and prognostic significance of cytoplasmic expression of ELAV-like protein HuR in invasive breast cancer treated with neoadjuvant chemotherapy.
Wang J; Li D; Wang B; Wu Y
Breast Cancer Res Treat; 2013 Sep; 141(2):213-24. PubMed ID: 24036660
[TBL] [Abstract][Full Text] [Related]
12. A pharmacophore-based classification better predicts the outcomes of HER2-negative breast cancer patients receiving the anthracycline- and/or taxane-based neoadjuvant chemotherapy.
Li X; Sun H; Liu Q; Liu Y; Hou Y; Jin W
Cancer Med; 2021 Jul; 10(13):4658-4674. PubMed ID: 34076352
[TBL] [Abstract][Full Text] [Related]
13. FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer.
Kawase M; Toyama T; Takahashi S; Sato S; Yoshimoto N; Endo Y; Asano T; Kobayashi S; Fujii Y; Yamashita H
Breast Cancer; 2015 May; 22(3):308-16. PubMed ID: 23771556
[TBL] [Abstract][Full Text] [Related]
14. Polo-like kinase 4 (Plk4) potentiates anoikis-resistance of p53KO mammary epithelial cells by inducing a hybrid EMT phenotype.
Fonseca I; Horta C; Ribeiro AS; Sousa B; Marteil G; Bettencourt-Dias M; Paredes J
Cell Death Dis; 2023 Feb; 14(2):133. PubMed ID: 36797240
[TBL] [Abstract][Full Text] [Related]
15. PLK4 overexpression and its effect on centrosome regulation and chromosome stability in human gastric cancer.
Shinmura K; Kurabe N; Goto M; Yamada H; Natsume H; Konno H; Sugimura H
Mol Biol Rep; 2014 Oct; 41(10):6635-44. PubMed ID: 24981932
[TBL] [Abstract][Full Text] [Related]
16. Discovery of Polo-like Kinase 4 Inhibitors for the Treatment of Cancer: A Mini Patent Review.
Shu Y; Liu Y; Bian S; Xie Z; Liao C
Mini Rev Med Chem; 2023; 23(1):67-79. PubMed ID: 35657046
[TBL] [Abstract][Full Text] [Related]
17. A nine-lncRNA signature predicts distant relapse-free survival of HER2-negative breast cancer patients receiving taxane and anthracycline-based neoadjuvant chemotherapy.
Sun M; Liu X; Xia L; Chen Y; Kuang L; Gu X; Li T
Biochem Pharmacol; 2021 Jul; 189():114285. PubMed ID: 33069665
[TBL] [Abstract][Full Text] [Related]
18. MicroRNAs miR-7 and miR-340 predict response to neoadjuvant chemotherapy in breast cancer.
Raychaudhuri M; Bronger H; Buchner T; Kiechle M; Weichert W; Avril S
Breast Cancer Res Treat; 2017 Apr; 162(3):511-521. PubMed ID: 28181130
[TBL] [Abstract][Full Text] [Related]
19. YLT-11, a novel PLK4 inhibitor, inhibits human breast cancer growth via inducing maladjusted centriole duplication and mitotic defect.
Lei Q; Xiong L; Xia Y; Feng Z; Gao T; Wei W; Song X; Ye T; Wang N; Peng C; Li Z; Liu Z; Yu L
Cell Death Dis; 2018 Oct; 9(11):1066. PubMed ID: 30337519
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
